Impaired HMG-CoA Reductase Activity Caused by Genetic Variants or Statin Exposure: Impact on Human Adipose Tissue, β-Cells and Metabolome
Authors:
- Assel SarsenbayevaASAssel Sarsenbayeva
- Bipasha Nandi JuiBJBipasha Nandi Jui
- Giovanni FanniGFGiovanni Fanni
- Pedro BarbosaPBPedro Barbosa
- Fozia AhmedFAFozia Ahmed
- Robin KristófiRKRobin Kristófi
- Jing CenJCJing Cen
- Azazul ChowdhuryACAzazul Chowdhury
- Stanko SkrticSSStanko Skrtic
- Peter BergstenPBPeter Bergsten
- Tove FallTFTove Fall
- Jan W. ErikssonJan W. Eriksson
Open Access
- 25 August 2021
- journal article
- research article
- Published by MDPI AG in Metabolites
- Vol. 11 (9) , 574
Abstract
Inhibition of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase is associated with an increased risk of new-onset type 2 diabetes. We studied the association of genetic or pharmacological HMG-CoA reductase inhibition with plasma and adipose tissue (AT) metabolome and AT metabolic pathways. We also investigated the effects of statin-mediated pharmacological inhibition of HMG-CoA reductase on systemic insulin sensitivity by measuring the HOMA-IR index in subjects with or without statin therapy. The direct effects of simvastatin (20–250 nM) or its active metabolite simvastatin hydroxy acid (SA) (8–30 nM) were investigated on human adipocyte glucose uptake, lipolysis, and differentiation and pancreatic insulin secretion. We observed that the LDL-lowering HMGCR rs12916-T allele was negatively associated with plasma phosphatidylcholines and sphingomyelins, and HMGCR expression in AT was correlated with various metabolic and mitochondrial pathways. Clinical data showed that statin treatment was associated with HOMA-IR index after adjustment for age, sex, BMI, HbA1c, LDL-c levels, and diabetes status in the subjects. Supra-therapeutic concentrations of simvastatin reduced glucose uptake in adipocytes and normalized fatty acid-induced insulin hypersecretion from β-cells. Our data suggest that inhibition of HMG-CoA reductase is associated with insulin resistance. However, statins have a very mild direct effect on AT and pancreas, hence, other tissues as the liver or muscle appear to be of greater importance.Keywords
Funding Information
- Excellence Of Diabetes Research in Sweden (EXODIAB) (N/A)
- European Commision via the Marie Sklodowska Curie Innovative Training Network TREAT-MENT (H2020-MSCA-ITN-721236)
- Uppsala University Hospital ALF Grants (N/A)
- Svenska Sällskapet för Medicinsk Forskning (Swedish Society for Medical Research) (N/A)
- Diabetes Foundation (Swedish Diabetes Association) (N/A)
- Ernfors Foundation (N/A)
This publication has 61 references indexed in Scilit:
- Are statins diabetogenic?Current Opinion in Cardiology, 2011
- What is a relevant statin concentration in cell experiments claiming pleiotropic effects?British Journal of Clinical Pharmacology, 2011
- Purification of RNA Using TRIzol (TRI Reagent)Cold Spring Harbor Protocols, 2010
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 2010
- Impact of Simvastatin on Adipose Tissue: Pleiotropic Effects in VivoEndocrinology, 2009
- Simvastatin Suppresses Leptin Expression in 3T3-L1 Adipocytes via Activation of the Cyclic AMP–PKA Pathway Induced by Inhibition of Protein PrenylationThe Journal of Biochemistry, 2009
- Simvastatin Improves Flow-Mediated Dilation but Reduces Adiponectin Levels and Insulin Sensitivity in Hypercholesterolemic PatientsDiabetes Care, 2008
- Human SGBS Cells – a Unique Tool for Studies of Human Fat Cell BiologyObesity Facts, 2008
- Chemical, pharmacokinetic and pharmacodynamic properties of statins: an updateFundamental & Clinical Pharmacology, 2004
- Changes in phsophatidylcholine fatty acid composition are associated with altered skeletal muscle insulin responsiveness in normal manMetabolism, 2000